The complex regulation of TGF-ß in cardiovascular disease
Received 14 July 2012
Accepted for publication 15 August 2012
Published 13 September 2012 Volume 2012:8 Pages 533—539
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Santiago Redondo, Jorge Navarro-Dorado, Marta Ramajo, Úrsula Medina, Teresa Tejerina
Department of Pharmacology, School of Medicine, Universidad Complutense, Madrid, Spain
Abstract: Transforming growth factor β (TGF-β1) is a pleiotropic cytokine with many and complex effects in cell and tissue physiology. This is made possible by a very complex and interwoven signaling system, whose regulation continues to be the focus of a growing line of research. This complex regulation translates to a key role in cardiovascular physiology, hemostasis, and the blood–vessel interface. In accordance with this, the TGF-β1 pathway appears to be deregulated in related disorders, such as atherosclerotic vascular disease and myeloproliferative syndromes. It is expected that the growing amount of experimental and clinical research will yield medical advances in the applications of knowledge of the TGF-β1 pathway to diagnosis and therapeutics.
Keywords: transforming growth factor beta, pathway, Smads, non-Smads, atherosclerosis, myeloproliferative syndromes
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.